Marina Biotech (NASDAQ: MRNA) said today it has raised $5.1 million in a new securities offering. The company sold about 6.4 million units at 80 cents apiece. Each unit was composed of one share and 0.1746 warrants to buy future shares. The Bothell, WA-based company said it plans to use the money to run a clinical trial of a drug candidate for Familial Adenomatous Polyposis (FAP). Roth Capital Partners managed the transaction.